NeuroSense Therapeutics Ltd (NRSN) saw an uptrend of 18.98% in the recent trading with $1.63 being its most recent. The current price level 8.67% lower than the highest price of $1.50 marked by the stock while trading over the past 52-weeks, whereas it is 218.36% higher than the lowest price of $0.51 the company dropped to over past 52-weeks. The latest news story on NRSN appeared in (PR Newswire) under the title “NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch”.
Looking into the simple moving average, NeuroSense Therapeutics Ltd (NRSN)’s stock stands at a SMA-50 of $1.0689 while that of 5-day is reading $1.3596.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and NRSN’s SMA-200 as of now is $1.0852.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
NeuroSense Therapeutics Ltd Earnings – What Happened With NRSN
Coming around sales and income figures on NRSN Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
NRSN – NeuroSense Therapeutics Ltd Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 23.23 million. NRSN does have institutional investors; and they hold 0.81% of the stock.
NeuroSense Therapeutics Ltd – Insider Activity and Holdings
As on 2024-06-30, ARMISTICE CAPITAL, LLC was the top most holder in NeuroSense Therapeutics Ltd (NASDAQ:NRSN) with an ownership of 1.58 million shares of the company or 10.2822 of the stake worth $1.77 million. The filing also reveals MEITAV INVESTMENT HOUSE LTD as the second largest holder in the company with a control over 0.2597 of the outstanding shares. Its stake is worth $44800.0 for having 40000.0 shares in hand.
XTX TOPCO LTD also came holding a key position in the company during the recent quarter and it now holds 0.2119 of the outstanding shares. With this there are now 11.0 institutions which have possession in NRSN’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, NeuroSense Therapeutics Ltd has a debt to equity ratio of 0.03.
Technical Analysis of NeuroSense Therapeutics Ltd (NASDAQ:NRSN) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for NeuroSense Therapeutics Ltd (NRSN), we notice that the stock’s 20-day average volume is at 196,700 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 175,722 shares. And to end, NRSN’s 100-day average volume is 165,765 shares with 100% of the long-term indicators pointing towards Buy for the stock.
